Sanofi (SAN) News Today €80.93 +0.09 (+0.11%) As of 08/8/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSustainabilityBuy This Stock Why Is Sanofi Up Today?Toggle Visibility of Why Is Sanofi Up Today?Sanofi (SAN): Recent News Impacting Stock Sentiment Positive Sentiment: JP Morgan upgraded Sanofi’s ADR, signaling increased analyst confidence.JP Morgan Upgrades Sanofi - Depositary Receipt () (SNY) Positive Sentiment: Sanofi launched a pivotal Phase 3 trial in type 1 diabetes, which could be a game-changer for its diabetes portfolio.Sanofi’s New Phase 3 Study: A Potential Game-Changer in Type 1 Diabetes Treatment Positive Sentiment: Sanofi completed its acquisition of Vigil Neuroscience to bolster its neurodegenerative disease pipeline.Sanofi completes the acquisition of Vigil Neuroscience Neutral Sentiment: Sanofi was featured among the top biotech deals of July, underlining its active dealmaking strategy.Top biotech deals in July 2025 Neutral Sentiment: An FDA Action Alert highlighted pipeline reviews involving Sanofi alongside peers, without specific new holds or approvals.FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More Neutral Sentiment: Sanofi ramped up investments in digital drugmaking to streamline its R&D processes.Sanofi All In on Digital Drugmaking Negative Sentiment: RFK Jr. canceled 22 BARDA-funded mRNA vaccine projects, potentially cutting into Sanofi’s vaccine pipeline opportunities.RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA Negative Sentiment: A U.S. appeals court reinstated a drug-price conspiracy lawsuit against Sanofi, re-exposing the company to legal risk.US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies Negative Sentiment: Sanofi agreed to cover the majority of future Nuvaxovid study costs, which could weigh on near-term cash flow.Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification Negative Sentiment: An O’Reilly-led lawsuit alleges that prescription managers and manufacturers inflated insulin costs, which may draw Sanofi into costly litigation.O'Reilly lawsuit alleges prescription managers, manufacturers inflate insulin costs Posted 1+ days agoAI Generated. May Contain Errors. SAN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period JP Morgan Upgrades Sanofi - Depositary Receipt () (SNY)August 8 at 3:38 PM | msn.comSanofi’s New Phase 3 Study: A Potential Game-Changer in Type 1 Diabetes TreatmentAugust 8 at 5:35 AM | msn.comUS appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companiesAugust 7, 2025 | reuters.comNovavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership DiversificationAugust 7, 2025 | msn.comO'Reilly lawsuit alleges prescription managers, manufacturers inflate insulin costsAugust 7, 2025 | msn.comWhat's Driving the Market Sentiment Around Sanofi?August 5, 2025 | benzinga.comSanofi Consumer Healthcare spurts after Q2 resultsAugust 5, 2025 | msn.comRegeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.August 1, 2025 | msn.comSanofi raises annual sales growth expectations on strong Dupixent demandJuly 31, 2025 | msn.comSanofi Upbeat on Sales Outlook After Faster-Than-Expected GrowthJuly 31, 2025 | msn.comNew model predicts mRNA protein production, accelerating drug and vaccine discoveryJuly 26, 2025 | msn.comKling Bio and Sanofi link for antibodies and epitopes discoveryJuly 25, 2025 | msn.comNew AI tool accelerates mRNA-based treatments for viruses, cancers, genetic disordersJuly 25, 2025 | msn.comSanofi concludes Blueprint Medicines acquisitionJuly 21, 2025 | finance.yahoo.comSanofi: Sanofi completes acquisition of Blueprint MedicinesJuly 18, 2025 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Sarepta Therapeutics (SRPT)July 18, 2025 | theglobeandmail.comThermo Fisher acquires Sanofi’s steriles manufacturing site in USJuly 17, 2025 | finance.yahoo.comEmcure, Sanofi tie up for anti-diabetic rangeJuly 17, 2025 | msn.comEmcure, Sanofi ink distribution pact for oral anti-diabetic products in IndiaJuly 16, 2025 | msn.comSanofi Geographic Atrophy Treatment Gets FDA's Fast Track DesignationJuly 16, 2025 | marketwatch.comThermo Fisher Scientific Expands Partnership with SanofiJuly 16, 2025 | marketwatch.comPress Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degenerationJuly 16, 2025 | finance.yahoo.comSanofi begins shipping flu vaccines for 2025-2026 seasonJuly 11, 2025 | au.investing.comNurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead PaymentsJuly 10, 2025 | msn.comPomerantz LLP: INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNYJuly 9, 2025 | finanznachrichten.deSanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDPJuly 1, 2025 | finance.yahoo.comSanofi: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathyJune 30, 2025 | finanznachrichten.deFDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoidJune 25, 2025 | finance.yahoo.comSanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin DiseaseJune 21, 2025 | uk.finance.yahoo.comSanofi: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoidJune 20, 2025 | finanznachrichten.deRegeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays DullJune 20, 2025 | msn.comDoH, Sanofi partner to accelerate development of new global vaccines in Abu DhabiJune 19, 2025 | msn.comFDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZenecaJune 10, 2025 | msn.comSanofi: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV seasonJune 9, 2025 | finanznachrichten.deSanofi Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV seasonJune 9, 2025 | finanznachrichten.deTop global stories this week: UBS, Toyota Motor, Sanofi among major namesJune 8, 2025 | msn.comSanofi to Buy Blueprint for $9.1 Billion Equity ValueJune 2, 2025 | msn.comSanofi buys US biopharma group Blueprint in $9.1 billion dealJune 2, 2025 | msn.comSanofi: Finding Value In The Wake Of Itepekimab's DisappointmentMay 31, 2025 | seekingalpha.comSanofi, Regeneron shares nosedive after mixed Itepekimab resultsMay 30, 2025 | finance.yahoo.comStock Movers: Sanofi Down, M&G Up, Gap Down (podcast)May 30, 2025 | bloomberg.comSanofi, Regeneron’s Itepekimab Delivers Mixed Results in Late-Stage TrialsMay 30, 2025 | msn.comSanofi Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programsMay 29, 2025 | finanznachrichten.deSanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent StruggleMay 29, 2025 | finance.yahoo.comSanofi transfers vaccine production technology to VNVCMay 27, 2025 | msn.comSanofi exploring vaccine production in Vietnam with local partnerMay 27, 2025 | msn.comSanofi Sanofi completes acquisition of DR-0201May 27, 2025 | finanznachrichten.deC4X Discovery Holdings PLC: C4X Discovery receives latest milestone payment from SanofiMay 27, 2025 | finanznachrichten.deSanofi Redefines R&D strategy with AI: Vanguards of Health CareMay 22, 2025 | bloomberg.comNovavax Shares Jump After Long-Awaited FDA Approval of Its COVID-19 VaccineMay 21, 2025 | msn.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Email Address SAN Media Mentions By Week SAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAN News Sentiment▼-0.030.48▲Average Medical News Sentiment SAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAN Articles This Week▼75▲SAN Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Deutsche Bank Aktiengesellschaft News Today Bayer Aktiengesellschaft News Today Fielmann Group News Today Fresenius SE & Co. KGaA News Today Genfit News Today Sartorius Stedim Biotech News Today Siemens Healthineers News Today Merck KGaA News Today Fresenius Medical Care News Today Sartorius Aktiengesellschaft News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (EPA:SAN) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale